JP2022529166A5 - - Google Patents
Info
- Publication number
- JP2022529166A5 JP2022529166A5 JP2021561778A JP2021561778A JP2022529166A5 JP 2022529166 A5 JP2022529166 A5 JP 2022529166A5 JP 2021561778 A JP2021561778 A JP 2021561778A JP 2021561778 A JP2021561778 A JP 2021561778A JP 2022529166 A5 JP2022529166 A5 JP 2022529166A5
- Authority
- JP
- Japan
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962836019P | 2019-04-18 | 2019-04-18 | |
| US62/836,019 | 2019-04-18 | ||
| US201962946191P | 2019-12-10 | 2019-12-10 | |
| US62/946,191 | 2019-12-10 | ||
| PCT/US2020/028579 WO2020214853A1 (en) | 2019-04-18 | 2020-04-16 | Tetrahydro-1h-cyclopenta[cd]indene derivatives as hypoxia inducible factor-2(alpha) inhibitors |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2022529166A JP2022529166A (ja) | 2022-06-17 |
| JPWO2020214853A5 JPWO2020214853A5 (https=) | 2023-04-18 |
| JP2022529166A5 true JP2022529166A5 (https=) | 2023-04-18 |
| JP7581236B2 JP7581236B2 (ja) | 2024-11-12 |
Family
ID=71094790
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021561778A Active JP7581236B2 (ja) | 2019-04-18 | 2020-04-16 | 低酸素誘導因子２（アルファ）阻害剤としてのテトラヒドロ－１Ｈ－シクロペンタ［ｃｄ］インデン誘導体 |
Country Status (14)
| Country | Link |
|---|---|
| US (6) | US20200361855A1 (https=) |
| EP (1) | EP3956299A1 (https=) |
| JP (1) | JP7581236B2 (https=) |
| KR (1) | KR20210154191A (https=) |
| CN (3) | CN118993938A (https=) |
| AU (1) | AU2020260130C1 (https=) |
| CA (1) | CA3136650A1 (https=) |
| IL (1) | IL287258B2 (https=) |
| MX (1) | MX2021012549A (https=) |
| SG (1) | SG11202111118YA (https=) |
| TW (1) | TWI871313B (https=) |
| UA (1) | UA128792C2 (https=) |
| WO (1) | WO2020214853A1 (https=) |
| ZA (1) | ZA202108270B (https=) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020055883A1 (en) | 2018-09-11 | 2020-03-19 | Nikang Therapeutics, Inc. | 2,3-DIHYDROBENZO[b]THIOPHENE DERIVATIVES AS HYPOXIA INDUCIBLE FACTOR-2(ALPHA) INHIBITORS |
| EP3866927A4 (en) | 2018-10-17 | 2022-07-27 | Nikang Therapeutics, Inc. | Indane derivatives as hypoxia inducible factor-2(alpha) inhibitors |
| IL287258B2 (en) | 2019-04-18 | 2026-01-01 | Nikang Therapeutics Inc | Inhibitors as tetrahydro-1h-cyclopenta[cd] indene derivatives as hypoxia inducible factor -2alpha |
| US20220274914A1 (en) * | 2019-07-22 | 2022-09-01 | Nikang Therapeutics, Inc. | Tricyclic derivatives as hypoxia inducible factor-2(alpha) inhibitors |
| CN115298165B (zh) | 2020-03-19 | 2024-09-17 | 艾库斯生物科学有限公司 | 作为HIF-2α抑制剂的四氢化萘和四氢喹啉化合物 |
| US11420936B2 (en) | 2020-04-16 | 2022-08-23 | Nikang Therapeutics, Inc. | Hypoxia inducible factor-2(alpha) inhibitors and their use in the treatment of diseases |
| EP4136069A1 (en) * | 2020-04-16 | 2023-02-22 | Nikang Therapeutics, Inc. | Hypoxia inducible factor-2(alpha) inhibitors and their use in the treatment of diseases |
| CN114315552B (zh) * | 2020-09-30 | 2024-08-02 | 江西济民可信集团有限公司 | 三并环类化合物及其制备方法和应用 |
| WO2022082329A1 (en) * | 2020-10-19 | 2022-04-28 | Nikang Therapeutics, Inc. | Processes of preparing 3-fluoro-5- ( ( (1s, 2ar) -1, 3, 3, 4, 4-pentafluoro-2a-hydroxy-2, 2a, 3, 4-tetrahydro-1h-cyclopenta [cd] inden-7-yl) oxy) -benzonitrile |
| WO2022082337A1 (en) * | 2020-10-19 | 2022-04-28 | Nikang Therapeutics, Inc. | Process of preparing 3-fluoro-5 ( ( (1r, 2ar) -3, 3, 4, 4-tetrafluoro-1, 2a-dihydroxy-2, 2a, 3, 4-tetrahydro-1h-cyclopenta [cd] inden-7-yl) oxy) benzonitrile |
| WO2022086882A1 (en) | 2020-10-21 | 2022-04-28 | Nikang Therapeutics, Inc. | Diagnostic and therapeutic methods for treatment of cancer with a hif-2(alpha) inhibitor |
| US20220251218A1 (en) * | 2021-02-10 | 2022-08-11 | Gnt Biotech & Medicals Corporation | Pharmaceutical combination and method for overcoming immune suppression or stimulating immune response against cancer |
| CN121824485A (zh) * | 2021-02-23 | 2026-04-10 | 上海济煜医药科技股份有限公司 | 作为HIF2α抑制剂的三并环类化合物及其制备方法和应用 |
| US12145901B1 (en) | 2021-09-17 | 2024-11-19 | Arcus Biosciences, Inc. | Process for preparing tetralin compounds |
| WO2023060431A1 (en) | 2021-10-12 | 2023-04-20 | Nikang Therapeutics, Inc. | Processes of making 3-fluoro-5- ( ( (1s, 2ar) -1, 3, 3, 4, 4-pentafluoro-2a-hydroxy-2, 2a, 3, 4-tetrahydro-1h-cyclopenta [cd] inden-7-yl) oxy) -benzonitrile and polymorphs thereof |
| US12415779B2 (en) | 2021-10-12 | 2025-09-16 | Nikang Therapeutics, Inc. | Processes of making 3-fluoro-5-(((1S,2aR)-1,3,3,4,4-pentafluoro-2a-hydroxy-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-7-yl)oxy)-benzonitrile and polymorphs thereof |
| CA3235013A1 (en) * | 2021-10-18 | 2023-04-27 | Jing Lu | Hypoxia inducible factor-2(alpha) inhibitors for the treatment of bladder cancer |
| WO2023070483A1 (en) | 2021-10-29 | 2023-05-04 | Nikang Therapeutics, Inc. | PROCESSES OF MAKING 3-FLUORO-5- ( ( (1R, 2S, 2aS) -1, 2, 3, 3, 4, 4-HEXAFLUORO-2A-HYDROXY-2, 2A, 3, 4-TETRAHYDRO-1H-CYCLOPENTA [CD] INDEN-7-YL) -OXY) -BENZONITRILE AND POLYMORPHS THEREOF |
| WO2024240240A1 (zh) * | 2023-05-24 | 2024-11-28 | 江苏恩华药业股份有限公司 | 一种咪唑衍生物、中间体、制备方法及其应用 |
| WO2025231006A1 (en) | 2024-05-03 | 2025-11-06 | Nikang Therapeutics, Inc. | Pharmaceutical compositions of 3-fluoro-5-(((1s,2ar)-1,3,3,4,4- pentafluoro-2a-hydroxy-2,2a,3,4-tetrahydro-1h- cyclopenta[cd]inden-7-yl)oxy)-benzonitrile |
| WO2025230942A1 (en) | 2024-05-03 | 2025-11-06 | Nikang Therapeutics, Inc. | Pharmaceutical compositions of 3-fluoro-5-(((ls,2ar)-l,3,3,4,4-pentafluoro-2a-hydroxy-2,2a,3,4-tetrahydro-1h-cyclopenta[cd]inden-7-yl)oxy)-benzonitrile |
| WO2025235034A1 (en) * | 2024-05-04 | 2025-11-13 | Nikang Therapeutics, Inc. | 3-fluoro-5-(((ls,2ar)-1,3,3,4, 4-pentafluoro-2a-hydroxy-2,2a, 3,4-tetrahydro-lh-cyclopenta[cd]inden-7- yl)oxy)- benzonitrile dosing regimen for use in the treatment of cancer |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1997049388A1 (en) | 1996-06-26 | 1997-12-31 | Chugai Seiyaku Kabushiki Kaisha | Remedies for renal diseases and organ-preserving agents |
| WO2005118580A2 (en) | 2004-05-12 | 2005-12-15 | The Government Of The United States Of America As Represented By The Secretary, Department Of Health | Tricyclic compounds as inhibitors of the hypoxic signaling pathway |
| WO2006094292A2 (en) | 2005-03-02 | 2006-09-08 | Fibrogen, Inc. | Thienopyridine compounds, and methods of use thereof |
| EP2717870B1 (en) | 2011-06-06 | 2017-09-27 | Akebia Therapeutics Inc. | Composition for stabilizing hypoxia inducible factor-2 alpha useful for treating cancer |
| US9206134B2 (en) * | 2011-07-22 | 2015-12-08 | Beijing Betta Pharmaceuticals Co. Ltd. | Polymorphic forms of compounds as prolyl hydroxylase inhibitor, and uses thereof |
| WO2015035223A1 (en) * | 2013-09-09 | 2015-03-12 | Peloton Therapeutics, Inc. | Aryl ethers and uses thereof |
| ES2737148T3 (es) | 2013-12-16 | 2020-01-10 | Peloton Therapeutics Inc | Análogos de sulfona y sulfoximina cíclicos y usos de los mismos |
| US10098878B2 (en) | 2014-10-10 | 2018-10-16 | The Board Of Regents Of The University Of Texas System | HIF-2α inhibitors for treating iron overload disorders |
| US10807948B2 (en) | 2015-03-11 | 2020-10-20 | Peloton Therapeutics, Inc. | Aromatic compounds and uses thereof |
| US10278942B2 (en) | 2015-03-11 | 2019-05-07 | Peloton Therapeutics, Inc. | Compositions for use in treating pulmonary arterial hypertension |
| WO2016144826A1 (en) | 2015-03-11 | 2016-09-15 | Peloton Therapeutics, Inc. | Substituted pyridines and uses thereof |
| WO2016168510A1 (en) * | 2015-04-17 | 2016-10-20 | Peloton Therapeutics, Inc. | Combination therapy of a hif-2-alpha inhibitor and an immunotherapeutic agent and uses thereof |
| US9796697B2 (en) * | 2015-06-12 | 2017-10-24 | Peloton Therapeutics, Inc. | Tricyclic inhibitors of HIF-2-alpha and uses thereof |
| WO2017053192A1 (en) | 2015-09-21 | 2017-03-30 | The Board Of Regents Of The University Of Texas System | Biomarkers of response to hif-2-alpha inhibition in cancer and methods for the use thereof |
| WO2018031680A1 (en) * | 2016-08-10 | 2018-02-15 | Fronthera U.S. Pharmaceuticals Llc | Novel compounds, uses and methods for their preparation |
| WO2019052133A1 (zh) * | 2017-09-15 | 2019-03-21 | 苏州科睿思制药有限公司 | Gsk1278863的晶型及其制备方法和制药用途 |
| WO2019191227A1 (en) | 2018-03-28 | 2019-10-03 | Peloton Therapeutics, Inc. | Methods of reducing inflammation of the digestive system with inhibitors of hif-2-alpha |
| WO2020055883A1 (en) | 2018-09-11 | 2020-03-19 | Nikang Therapeutics, Inc. | 2,3-DIHYDROBENZO[b]THIOPHENE DERIVATIVES AS HYPOXIA INDUCIBLE FACTOR-2(ALPHA) INHIBITORS |
| EP3866927A4 (en) | 2018-10-17 | 2022-07-27 | Nikang Therapeutics, Inc. | Indane derivatives as hypoxia inducible factor-2(alpha) inhibitors |
| IL287258B2 (en) * | 2019-04-18 | 2026-01-01 | Nikang Therapeutics Inc | Inhibitors as tetrahydro-1h-cyclopenta[cd] indene derivatives as hypoxia inducible factor -2alpha |
| US20220274914A1 (en) | 2019-07-22 | 2022-09-01 | Nikang Therapeutics, Inc. | Tricyclic derivatives as hypoxia inducible factor-2(alpha) inhibitors |
| US11420936B2 (en) * | 2020-04-16 | 2022-08-23 | Nikang Therapeutics, Inc. | Hypoxia inducible factor-2(alpha) inhibitors and their use in the treatment of diseases |
| EP4136069A1 (en) | 2020-04-16 | 2023-02-22 | Nikang Therapeutics, Inc. | Hypoxia inducible factor-2(alpha) inhibitors and their use in the treatment of diseases |
| WO2022082329A1 (en) | 2020-10-19 | 2022-04-28 | Nikang Therapeutics, Inc. | Processes of preparing 3-fluoro-5- ( ( (1s, 2ar) -1, 3, 3, 4, 4-pentafluoro-2a-hydroxy-2, 2a, 3, 4-tetrahydro-1h-cyclopenta [cd] inden-7-yl) oxy) -benzonitrile |
| WO2022082337A1 (en) | 2020-10-19 | 2022-04-28 | Nikang Therapeutics, Inc. | Process of preparing 3-fluoro-5 ( ( (1r, 2ar) -3, 3, 4, 4-tetrafluoro-1, 2a-dihydroxy-2, 2a, 3, 4-tetrahydro-1h-cyclopenta [cd] inden-7-yl) oxy) benzonitrile |
| US12415779B2 (en) | 2021-10-12 | 2025-09-16 | Nikang Therapeutics, Inc. | Processes of making 3-fluoro-5-(((1S,2aR)-1,3,3,4,4-pentafluoro-2a-hydroxy-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-7-yl)oxy)-benzonitrile and polymorphs thereof |
| CA3235013A1 (en) | 2021-10-18 | 2023-04-27 | Jing Lu | Hypoxia inducible factor-2(alpha) inhibitors for the treatment of bladder cancer |
-
2020
- 2020-04-16 IL IL287258A patent/IL287258B2/en unknown
- 2020-04-16 KR KR1020217037203A patent/KR20210154191A/ko active Pending
- 2020-04-16 SG SG11202111118YA patent/SG11202111118YA/en unknown
- 2020-04-16 CA CA3136650A patent/CA3136650A1/en active Pending
- 2020-04-16 US US16/851,018 patent/US20200361855A1/en not_active Abandoned
- 2020-04-16 MX MX2021012549A patent/MX2021012549A/es unknown
- 2020-04-16 JP JP2021561778A patent/JP7581236B2/ja active Active
- 2020-04-16 WO PCT/US2020/028579 patent/WO2020214853A1/en not_active Ceased
- 2020-04-16 EP EP20733066.3A patent/EP3956299A1/en active Pending
- 2020-04-16 AU AU2020260130A patent/AU2020260130C1/en active Active
- 2020-04-16 UA UAA202105642A patent/UA128792C2/uk unknown
- 2020-04-16 CN CN202411099450.0A patent/CN118993938A/zh active Pending
- 2020-04-16 CN CN202411099453.4A patent/CN118993939A/zh active Pending
- 2020-04-16 CN CN202080027716.4A patent/CN113874350B/zh active Active
- 2020-04-17 TW TW109113096A patent/TWI871313B/zh active
-
2021
- 2021-03-30 US US17/218,129 patent/US11267782B2/en active Active
- 2021-07-15 US US17/377,356 patent/US20210347729A1/en not_active Abandoned
- 2021-10-26 ZA ZA2021/08270A patent/ZA202108270B/en unknown
-
2022
- 2022-02-11 US US17/670,423 patent/US11753366B2/en active Active
-
2023
- 2023-07-12 US US18/351,283 patent/US12391642B2/en active Active
-
2025
- 2025-07-15 US US19/270,361 patent/US20250340508A1/en active Pending